The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
Open accessAbstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder caused mainly by lack of dopamine in the brain. Dopamine is a neurotransmitter involved in movement, motivation, memory, and other functions; its level is decreased in PD brain as a result of dopaminergic cell death. Dopamine loss in PD brain is a cause of motor deficiency and, possibly, a reason of the cognitive deficit observed in some PD patients. PD is mostly not recognized in its early stage because of a long latency between the first damage to dopaminergic cells and the onset of clinical symptoms. Therefore, it is very important to find reliable molecular biomarkers that can distinguish PD from other conditions, monitor its progression, or give an indication of a positive response to a therapeutic intervention. PD biomarkers can be subdivided into four main types: clinical, imaging, biochemical, and genetic. For a long time protein biomarkers, dopamine metabolites, amino acids, etc. in blood, serum, cerebrospinal liquid (CSF) were considered the most promising. Among the candidate biomarkers that have been tested, various forms of α-synuclein (α-syn), i.e., soluble, aggregated, post-translationally modified, etc. were considered potentially the most efficient. However, the encouraging recent results suggest that microRNA-based analysis may bring considerable progress, especially if it is combined with α-syn data. Another promising analysis is the advanced metabolite profiling of body fluids, called "metabolomics" which may uncover metabolic fingerprints specific for various stages of PD. Conventional pharmacological treatment of PD is based on the replacement of dopamine using dopamine precursors (levodopa, L-DOPA, L-3,4 dihydroxyphenylalanine), dopamine agonists (amantadine, apomorphine) and MAO-B inhibitors (selegiline, rasagiline), which can be used alone or in combination with each other. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects. This review covers molecules that might act as the biomarkers of PD. Then, PD risk factors (including genetics and non-genetic factors) and PD treatment options are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 3×
“Current medical, pathological, and experimental data support the Braak hypothesis (Braak et al., 2003) of spatiotemporal spread of PD pathology involving α-syn propagation from the gastrointestinal and olfactory system via transsynaptic cell-to-cell transfer through the vegetative nervous systems to the CNS.”
BackgroundMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“2-q27 Parkin Ubiquitin-protein ligase (Kitada et al., 1988)”
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,205
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
Orexin A activates locus coeruleus cell firing and increases arousal in the rat
Hagan, J. J., Leslie, R. A., Patel, S., Evans, M. L., Wattam, T. A., Holmes, S., Benham, C. D., Taylor, S. G., Routledge, C., Hemmati, P., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10911 · Cited by 1,234
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Wang, E.-S., Yao, H.-B., Chen, Y.-H., Wang, G., Gao, W.-W., Sun, Y.-R., Guo, J.-G., Hu, J.-W., Jiang, C.-C., & Hu, J. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350082 · Cited by 1,176
Reactive oxygen species: from health to disease
Brieger, K., Schiavone, S., Miller Jr., F. J., & Krause, K.-H. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13659 · Cited by 1,133
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Bronstein, J. M., Tagliati, M., Alterman, R. L., Lozano, A. M., Volkmann, J., Stefani, A., Horak, F. B., Okun, M. S., Foote, K. D., Krack, P., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.260 · Cited by 971
Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies
Ciechanover, A., & Kwon, Y. T. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.117 · Cited by 898
Prion-like spreading of pathological α-synuclein in brain
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M. A., & Hasegawa, M. (2013) · Brain · doi:10.1093/brain/awt037 · Cited by 867
Oxidative processes and antioxidative defense mechanisms in the aging brain 1
Reiter, R. J. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.7.7737461 · Cited by 806
VPS35 mutations in Parkinson disease
Vilariño-Güell, C., Wider, C., Ross, O. A., Dachsel, J. C., Kachergus, J. M., Lincoln, S. J., Soto-Ortolaza, A. I., Cobb, S. A., Wilhoite, G. J., Bacon, J. A., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.001 · Cited by 800
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage.
Shigenaga, M. K., Gimeno, C. J., & Ames, B. N. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.9697 · Cited by 732 · cited 1×
“One of the DNA lesions caused by ROS is an oxidized form of 8-hydroxyguanine (8-OHG) known as 8-OHdG which can be used as a biomarker of DNA damage (Shigenaga et al., 1989).”
BackgroundBach, A. W., Lan, N. C., Johnson, D. L., Abell, C. W., Bembenek, M. E., Kwan, S. W., Seeburg, P. H., & Shih, J. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4934 · Cited by 723
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
Obeso, J. A., Rodríguez-Oroz, M. C., Benitez-Temino, B., Blesa, F. J., Guridi, J., Marin, C., & Rodriguez, M. (2008) · Movement Disorders · doi:10.1002/mds.22062 · Cited by 663
GABA and GABA Receptors in the Central Nervous System and Other Organs
Watanabe, M., Maemura, K., Kanbara, K., Tamayama, T., & Hayasaki, H. (2002) · International Review of Cytology · doi:10.1016/s0074-7696(02)13011-7 · Cited by 630
Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease
Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., Gasser, T., Wszolek, Z., Müller, T., Bornemann, A., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi215 · Cited by 568
Mechanisms of deep brain stimulation
Herrington, T. M., Cheng, J. J., & Eskandar, E. N. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00281.2015 · Cited by 551 · cited 1×
“Deep brain stimulation therapy is rarely used for certain types of brain-related disorders including PD, dystonia, obsessivecompulsive disorder and treatment resistant depression (Herrington et al., 2016).”
BackgroundPlaha, P. (2006) · Brain · doi:10.1093/brain/awl127 · Cited by 515
Mutations in NR4A2 associated with familial Parkinson disease
Le, W.-D., Xu, P., Jankovic, J., Jiang, H., Appel, S. H., Smith, R. G., & Vassilatis, D. K. (2003) · Nature Genetics · doi:10.1038/ng1066 · Cited by 487
Characterization of PLA2G6 as a locus for dystonia‐parkinsonism
Paisan‐Ruiz, C., Bhatia, K. P., Li, A., Hernandez, D., Davis, M., Wood, N. W., Hardy, J., Houlden, H., Singleton, A., & Schneider, S. A. (2009) · Annals of Neurology · doi:10.1002/ana.21415 · Cited by 480
Hypocretin (orexin) loss in Parkinson's disease
Fronczek, R., Overeem, S., Lee, S. Y. Y., Hegeman, I. M., van Pelt, J., van Duinen, S. G., Lammers, G. J., & Swaab, D. F. (2007) · Brain · doi:10.1093/brain/awm090 · Cited by 463
A delicate balance: Iron metabolism and diseases of the brain
Hare, D., Ayton, S., Bush, A., & Lei, P. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00034 · Cited by 443
PARK7, a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, on Chromosome 1p36
van Duijn, C. M., Dekker, M. C. J., Bonifati, V., Galjaard, R. J., Houwing-Duistermaat, J. J., Snijders, P. J. L. M., Testers, L., Breedveld, G. J., Horstink, M., Sandkuijl, L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/322996 · Cited by 379
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Krebs, C. E., Karkheiran, S., Powell, J. C., Cao, M., Makarov, V., Darvish, H., Di Paolo, G., Walker, R. H., Shahidi, G. A., Buxbaum, J. D., et al. (2013) · Human Mutation · doi:10.1002/humu.22372 · Cited by 336
DNAJC13 mutations in Parkinson disease
Vilariño-Güell, C., Rajput, A., Milnerwood, A. J., Shah, B., Szu-Tu, C., Trinh, J., Yu, I., Encarnacion, M., Munsie, L. N., Tapia, L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt570 · Cited by 313
Matsumoto, L., Takuma, H., Tamaoka, A., Kurisaki, H., Date, H., Tsuji, S., & Iwata, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015522 · Cited by 308
Berendse, H. W., Booij, J., Francot, C. M. J. E., Bergmans, P. L. M., Hijman, R., Stoof, J. C., & Wolters, E. C. (2001) · Annals of Neurology · doi:10.1002/ana.1049 · Cited by 299
Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease
Chartier-Harlin, M.-C., Dachsel, J. C., Vilariño-Güell, C., Lincoln, S. J., Leprêtre, F., Hulihan, M. M., Kachergus, J., Milnerwood, A. J., Tapia, L., Song, M.-S., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.08.009 · Cited by 299
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 298
A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity
Perni, M., Galvagnion, C., Maltsev, A., Meisl, G., Müller, M. B. D., Challa, P. K., Kirkegaard, J. B., Flagmeier, P., Cohen, S. I. A., Cascella, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610586114 · Cited by 298
Kikuchi, A., Takeda, A., Onodera, H., Kimpara, T., Hisanaga, K., Sato, N., Nunomura, A., Castellani, R. J., Perry, G., Smith, M. A., et al. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0466 · Cited by 289
Alpha-synuclein structure, functions, and interactions
Emamzadeh, F. N. (2016) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.181989 · Cited by 286
Self-citationα-Synuclein and dopamine at the crossroads of Parkinson's disease
Venda, L. L., Cragg, S. J., Buchman, V. L., & Wade-Martins, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.004 · Cited by 285
Seppi, K., Schocke, M. F. H., Esterhammer, R., Kremser, C., Brenneis, C., Mueller, J., Boesch, S., Jaschke, W., Poewe, W., & Wenning, G. K. (2003) · Neurology · doi:10.1212/01.wnl.0000049911.91657.9d · Cited by 256
HDL and cholesterol handling in the brain
Vitali, C., Wellington, C. L., & Calabresi, L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu148 · Cited by 254
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Bohnen, N. I., Albm, R. L., Koeppe, R. A., Wernette, K. A., Kilbourn, M. R., Minoshima, S., & Frey, K. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600276 · Cited by 254
Most effective stimulation site in subthalamic deep brain stimulation for Parkinson's disease
Herzog, J., Fietzek, U., Hamel, W., Morsnowski, A., Steigerwald, F., Schrader, B., Weinert, D., Pfister, G., Müller, D., Mehdorn, H. M., et al. (2004) · Movement Disorders · doi:10.1002/mds.20056 · Cited by 253
Membrane Association and Protein Conformation of α-Synuclein in Intact Neurons
McLean, P. J., Kawamata, H., Ribich, S., & Hyman, B. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8812 · Cited by 244
Neuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243
Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts
Saeed, U., Compagnone, J., Aviv, R. I., Strafella, A. P., Black, S. E., Lang, A. E., & Masellis, M. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0076-6 · Cited by 234
Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool
Iacobazzi, V., Castegna, A., Infantino, V., & Andria, G. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.07.012 · Cited by 230
Astrocytes and Therapeutics for Parkinson's Disease
Rappold, P. M., & Tieu, K. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.001 · Cited by 226
Parkinson’s disease from the gut
Liddle, R. A. (2018) · Brain Research · doi:10.1016/j.brainres.2018.01.010 · Cited by 219
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Bartus, R. T., Baumann, T. L., Siffert, J., Herzog, C. D., Alterman, R., Boulis, N., Turner, D. A., Stacy, M., Lang, A. E., Lozano, A. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182904faa · Cited by 215
Alpha synuclein is transported into and out of the brain by the blood-brain barrier
Sui, Y.-T., Bullock, K. M., Erickson, M. A., Zhang, J., & Banks, W. A. (2014) · Peptides · doi:10.1016/j.peptides.2014.09.018 · Cited by 212
Foulds, P. G., Mitchell, J. D., Parker, A., Turner, R., Green, G., Diggle, P., Hasegawa, M., Taylor, M., Mann, D., & Allsop, D. (2011) · The FASEB Journal · doi:10.1096/fj.10-179192 · Cited by 205
Yu, S., Li, X., Liu, G., Han, J., Zhang, C., Li, Y., Xu, S., Liu, C., Gao, Y., Yang, H., et al. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.12.028 · Cited by 194
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
Zeng, X.-S., Geng, W.-S., Jia, J.-J., Chen, L., & Zhang, P.-P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00109 · Cited by 193
Enteric GFAP expression and phosphorylation in Parkinson's disease
Clairembault, T., Kamphuis, W., Leclair‐Visonneau, L., Rolli‐Derkinderen, M., Coron, E., Neunlist, M., Hol, E. M., & Derkinderen, P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12742 · Cited by 191
DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability
Köroğlu, Ç., Baysal, L., Cetinkaya, M., Karasoy, H., & Tolun, A. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.11.006 · Cited by 190
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
The etiology of Parkinson's disease with emphasis on the MPTP story
Langston, J. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.153s · Cited by 180
Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease
Lautier, C., Goldwurm, S., Dürr, A., Giovannone, B., Tsiaras, W. G., Pezzoli, G., Brice, A., & Smith, R. J. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.015 · Cited by 178
Review of functional/anatomical imaging in oncology
Histed, S. N., Lindenberg, M. L., Mena, E., Turkbey, B., Choyke, P. L., & Kurdziel, K. A. (2012) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32834ec8a5 · Cited by 175
Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism?
Charles, P., Camuzat, A., Benammar, N., Sellal, F., Destée, A., Bonnet, A.-M., Lesage, S., Le Ber, I., Stevanin, G., Dürr, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000269323.21969.db · Cited by 166
Bernis, M. E., Babila, J. T., Breid, S., Wüsten, K. A., Wüllner, U., & Tamgüney, G. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0254-7 · Cited by 166
Parkinson’s disease is associated with DNA methylation levels in human blood and saliva
Chuang, Y.-H., Paul, K. C., Bronstein, J. M., Bordelon, Y., Horvath, S., & Ritz, B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0466-5 · Cited by 166
Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
Bartus, R. T., Weinberg, M. S., & Samulski, R. J. (2014) · Molecular Therapy · doi:10.1038/mt.2013.281 · Cited by 164
Epidemiologic studies of environmental exposures in Parkinson's disease
Elbaz, A., & Tranchant, C. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.06.024 · Cited by 164
Plasma α-synuclein is decreased in subjects with Parkinson's disease
Li, Q.-X., Mok, S. S., Laughton, K. M., McLean, C. A., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 160
Biomarker Research in Parkinson’s Disease Using Metabolite Profiling
Havelund, J. F., Heegaard, N. H. H., Færgeman, N. J., & Gramsbergen, J. B. (2017) · Metabolites · doi:10.3390/metabo7030042 · Cited by 154
Moghadam, A. K., Charsouei, S., Bell, B., & Jabalameli, M. R. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0587-4 · Cited by 154
Nagai, Y., Ueno, S., Saeki, Y., Soga, F., Hirano, M., & Yanagihara, T. (1996) · Neurology · doi:10.1212/wnl.46.3.791 · Cited by 150
The probable relation between Toxoplasma gondii and Parkinson's disease
Miman, Ö., Küsbeci, Ö. Y., Aktepe, O. C., & Çetınkaya, Z. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.057 · Cited by 150
Epigenetic mechanisms in Parkinson's disease
Feng, Y., Jankovic, J. J., & Wu, Y. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.12.017 · Cited by 146
Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers
Lee, H.-J., Baek, S. M., Ho, D. H., Suk, J., Cho, E.-D., & Lee, S. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.4.026 · Cited by 144
Recent advances in treating Parkinson’s disease
Oertel, W. H. (2017) · F1000Research · doi:10.12688/f1000research.10100.1 · Cited by 144
Vermeiren, Y., & Deyn, P. P. D. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.11.009 · Cited by 134
Levin, J., Schmidt, F., Boehm, C., Prix, C., Bötzel, K., Ryazanov, S., Leonov, A., Griesinger, C., & Giese, A. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1265-3 · Cited by 132
Deurwaerdère, P. D., Giovanni, G. D., & Millan, M. J. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.07.002 · Cited by 131
The Proteasome Inhibition Model of Parkinson’s Disease
Bentea, E., Verbruggen, L., & Massie, A. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-160921 · Cited by 125
Wienecke, M., Werth, E., Poryazova, R., Baumann‐Vogel, H., Bassetti, C. L., Weller, M., Waldvogel, D., Storch, A., & Baumann, C. R. (2012) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2012.01027.x · Cited by 122
dos Santos, M. C. T., Barreto-Sanz, M. A., Correia, B. R. S., Bell, R., Widnall, C., Perez, L. T., Berteau, C., Schulte, C., Scheller, D., Berg, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24736 · Cited by 120
Angot, É., & Brundin, P. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70802-8 · Cited by 119
Parkinson's Disease: Gene Therapies
Coune, P., Schneider, B. L., & Aebischer, P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009431 · Cited by 114
Molecular imaging of dopamine transporters
Brooks, D. J. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2015.12.009 · Cited by 114
Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease
Blandini, F., Sinforiani, E., Pacchetti, C., Samuele, A., Bazzini, E., Zangaglia, R., Nappi, G., & Martignoni, E. (2006) · Neurology · doi:10.1212/01.wnl.0000198511.09968.b3 · Cited by 113
alpha-Synuclein forms a complex with transcription factor Elk-1
Iwata, A., Miura, S., Kanazawa, I., Sawada, M., & Nukina, N. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00232.x · Cited by 101
PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort
Shi, C., Tang, B., Wang, L., Lv, Z., Wang, J., Luo, L.-Z., Shen, L. H., Jiang, H. F., Yan, X., Pan, Q., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318221acd3 · Cited by 98
Wu, Y.-R., Lin, H.-Y., Chen, C.-M., Gwinn-Hardy, K., Ro, L., Wang, Y.-C., Li, S.-H., Hwang, J., Fang, K., Hsieh-Li, H., et al. (2004) · Clinical Genetics · doi:10.1111/j.0009-9163.2004.00213.x · Cited by 97
Adenosine A2A receptor gene disruption protects in an α‐synuclein model of Parkinson's disease
Kachroo, A., & Schwarzschild, M. A. (2011) · Annals of Neurology · doi:10.1002/ana.22630 · Cited by 97
Swanson, C. R., Berlyand, Y., Xie, S. X., Alcalay, R. N., Chahine, L. M., & Chen‐Plotkin, A. S. (2015) · Movement Disorders · doi:10.1002/mds.26290 · Cited by 94
Rinne, J. O., Ruottinen, H., Bergman, J., Haaparanta‐Solin, M., Sonninen, P. H., & Solin, O. H. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.6.737 · Cited by 94
Functional Neuroimaging in Parkinson's Disease
Niethammer, M., Feigin, A., & Eidelberg, D. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009274 · Cited by 90
Medical Management of Parkinson’s Disease
Encarnacion, E. V., & Hauser, R. A. (2009) · Springer eBooks · doi:10.1007/978-3-540-69960-6_90 · Cited by 89
Role of Orexin-A in Hypertension and Obesity
Imperatore, R., Palomba, L., & Cristino, L. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0729-y · Cited by 86
Intracellular Dynamics of Synucleins
Surguchov, A. P. (2015) · International review of cytology · doi:10.1016/bs.ircmb.2015.07.007 · Cited by 81
Self-citationHenchcliffe, C., Shungu, D. C., Mao, X., Huang, C. C., Nirenberg, M. J., Jenkins, B. G., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.037 · Cited by 79
Höllerhage, M., Moebius, C., Melms, J. C., Chiu, W., Goebel, J. N., Chakroun, T., Koeglsperger, T., Oertel, W. H., Rösler, T. W., Bickle, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11664-5 · Cited by 76
Medical Management of Parkinson's Disease
Goldenberg, M. M. (2012) · Springer eBooks · doi:10.1007/springerreference_143638 · Cited by 71
Molecular Mechanisms of Pathogenesis of Parkinson's Disease
Shadrina, M. I., Slominsky, P. A., & Sa, L. (2010) · International review of cytology · doi:10.1016/s1937-6448(10)81006-8 · Cited by 70
Therapeutic induction of autophagy to modulate neurodegenerative disease progression
Hochfeld, W. E., Lee, S. H. F., & Rubinsztein, D. C. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.189 · Cited by 70
SPECT Molecular Imaging in Parkinson's Disease
Wang, L., Zhang, Q., Li, H., & Zhang, H. (2012) · BioMed Research International · doi:10.1155/2012/412486 · Cited by 69
Wang, E.-S., Sun, Y. J., Guo, J., Gao, X., Hu, J., Zhou, L., Hu, J., & Jiang, C. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01318.x · Cited by 66
Fazio, P., Svenningsson, P., Forsberg, A., Jönsson, E. G., Amini, N., Nakao, R., Nag, S., Halldin, C., Farde, L., & Varrone, A. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.152421 · Cited by 61
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Emamzadeh, F. N. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0942-9 · Cited by 61
Self-citationMicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease
Arshad, A. R., Sulaiman, S. A., Saperi, A. A., Jamal, R., Ibrahim, N. M., & Murad, N. A. A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00352 · Cited by 60
Pirker, W., Asenbaum, S., Wenger, S., Kornhuber, J., Angelberger, P., Deecke, L., Podreka, I., & Brücke, T. (1997) · PubMed · Cited by 59
Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease
Goldstein, D. S., Holmes, C. S., Lopez, G. J., Wu, T., & Sharabi, Y. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.023 · Cited by 59
Human plasma proapoa-I: Isolation and amino-terminal sequence
Brewer, H. B., Fairwell, T., Kay, L. L., Meng, M., Ronan, R., Law, S. W. T., & Light, J. A. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)91772-2 · Cited by 58
The nonmotor features of Parkinson's disease: pathophysiology and management advances
Reichmann, H., Brandt, M., & Klingelhoefer, L. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000348 · Cited by 58
PE2I: A Radiopharmaceutical for In vivo Exploration of the Dopamine Transporter
Emond, P., Guilloteau, D., & Chalon, S. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1527-3458.2007.00033.x · Cited by 57
A haplotype at the PARK3 locus influences onset age for Parkinson’s disease: The Gene PD study
Karamohamed, S., DeStefano, A. L., Wilk, J. B., Shoemaker, C. M., Golbe, L. I., Mark, M. H., Lazzarini, A. M., Suchowersky, O., Labelle, N., Guttman, M., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000095966.99430.f4 · Cited by 56
Alcohol dehydrogenase alleles in Parkinson's disease
Buervenich, S., Sydow, O., Carmine, A., Zhang, Z., Anvret, M., & Olson, L. (2000) · Movement Disorders · Cited by 56
The MC1R melanoma risk variant p. R160W is associated with P arkinson disease
Tell‐Martí, G., Puig‐Butillé, J. A., Potrony, M., Bádenas, C., Milà, M., Malvehy, J., Martí, M. J., Ezquerra, M., Fernández‐Santiago, R., & Puig, S. (2015) · Annals of Neurology · doi:10.1002/ana.24373 · Cited by 56
Burke, W. J. (2003) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007033482913 · Cited by 55
Lin, C., Chen, M., Chen, G. S., Tai, C., & Wu, R. (2011) · Human Genetics · doi:10.1007/s00439-011-1041-6 · Cited by 55
Buervenich, S., Belin, A. C., Galter, D., Shahabi, H. N., Johnels, B., Holmberg, B., Ahlberg, J., Nissbrandt, H., Eerola, J., Hellström, O., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.74 · Cited by 51
Transcranial Sonography of the Substantia Nigra: Digital Image Analysis
Školoudík, D., Jelínková, M., Blahuta, J., Čermák, P., Soukup, T., Bártová, P., Langová, K., & Herzig, R. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4049 · Cited by 49
Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?
Martins-Branco, D. A., Esteves, A. R., Santos, D., Arduíno, D. M., Swerdlow, R. H., Oliveira, C. R., Januário, C., & Cardoso, S. M. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.008 · Cited by 48
Pore-Forming Proteins as Mediators of Novel Epigenetic Mechanism of Epilepsy
Surguchov, A. P., Surgucheva, I. G., Sharma, M., Sharma, R. A., & Singh, V. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00003 · Cited by 48
Self-citationTong, J., Wilson, A. A., Boileau, I., Houle, S., & Kish, S. J. (2008) · Synapse · doi:10.1002/syn.20573 · Cited by 44
Glucocerebrosidase mutations in Thai patients with Parkinson's disease
Pulkes, T., Choubtum, L., Chitphuk, S., Thakkinstian, A., Pongpakdee, S., Kulkantrakorn, K., Hanchaiphiboolkul, S., Tiamkao, S., & Boonkongchuen, P. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.06.007 · Cited by 37
Lin, K., Weng, Y.-H., Hsieh, C., Lin, W., Wey, S., Kung, M., Yen, T., Lu, C., & Hsiao, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075952 · Cited by 34
Peripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects
Simon, D. K., On behalf of the NINDS NET-PD Investigators, Simuni, T., Elm, J. J., Clark, J., Graebner, A. K., Baker, L., Dunlop, S. R., Emborg, M. E., Kamp, C., et al. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150666 · Cited by 32
Double, K. L., & Halliday, G. M. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_19 · Cited by 31
Kikuchi, Y., Yasuhara, T., Agari, T., Kondo, A., Kuramoto, S., Kameda, M., Kadota, T., Baba, T., Tajiri, N., Wang, F., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22467 · Cited by 31
Familial Mutations May Switch Conformational Preferences in α-Synuclein Fibrils
Xu, L., Ma, B., Nussinov, R., & Thompson, D. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00406 · Cited by 31
The correlation between Toxoplasma gondii infection and Parkinson’s disease: a case-control study
Oskouei, M. M., Hamidi, F., Talebi, M., Farhoudi, M., Taheraghdam, A., Kazemi, T., Sadeghi-Bazargani, H., & Fallah, E. (2016) · Journal of Parasitic Diseases · doi:10.1007/s12639-014-0595-3 · Cited by 28
Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials
Siderowf, A. D., Aarsland, D., Mollenhauer, B., Goldman, J. G., & Ravina, B. M. (2018) · Movement Disorders · doi:10.1002/mds.27355 · Cited by 28
Chung, E. J., Kim, E. G., Bae, J. S., Eun, C. K., Lee, K. S., Oh, M., & Kim, S. J. (2009) · Journal of Movement Disorders · doi:10.14802/jmd.09017 · Cited by 27
Goldstein, D. S. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53491-0.00029-8 · Cited by 27
Microtubule-associated protein tau (MAPT) influences the risk of Parkinson's disease among Indians
Das, G., Misra, A. K., Das, S. K., Ray, K., & Ray, J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.05.031 · Cited by 22
Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease
van der Zee, S., Vermeiren, Y., Fransén, E., Dam, D. V., Aerts, T., Gerritsen, M. J. J., Spikman, J. M., van Laar, T., & Deyn, P. P. D. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-171228 · Cited by 22
Non-synonymous GIGYF2 variants in Parkinson’s disease from two Asian populations
Tan, E., Lin, C.-H., Tai, C., Tan, L. C. S., Chen, M., Li, R., Lim, H., Ratnagopal, P., Yih, Y., Prakash, K. M., et al. (2009) · Human Genetics · doi:10.1007/s00439-009-0678-x · Cited by 20
The X‐Linked Dystonia‐Parkinsonism Syndrome (XDP): Clinical and Molecular Genetic Analysis
Graeber, M. B., & Müller, U. (1992) · Brain Pathology · doi:10.1111/j.1750-3639.1992.tb00706.x · Cited by 19
Takahashi, Y., Kanbayashi, T., Hoshikawa, M., Imanishi, A., Sagawa, Y., Tsutsui, K., Takeda, Y., Kusanagi, H., Nishino, S., & Shimizu, T. (2015) · Sleep and Biological Rhythms · doi:10.1111/sbr.12112 · Cited by 13
Yang, Z., Wang, X., Yang, J., Sun, M., Wang, X., & Wang, X. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9686-5 · Cited by 8
[Association of PARK 16 polymorphisms with Parkinson's disease in Han population of Suzhou area].
Li, D., Wang, J., Mao, C., Hu, W., Li, X., Yang, Y., Qin, Z., & Liu, C.-F. (2011) · PubMed · Cited by 3
Cited by
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
Oxidative stress and regulated cell death in Parkinson’s disease
Dionísio, P. A., Amaral, J. D., & Rodrigues, C. M. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101263 · Cited by 424
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Parkinson’s Disease: Pathogenesis and Clinical Aspects
(2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018 · Cited by 294
Picca, A., Guerra, F., Calvani, R., Romano, R., Coelho-Júnior, H. J., Bucci, C., & Marzetti, E. (2021) · Biomolecules · doi:10.3390/biom11101508 · Cited by 189
Metadata
- Authors
- Emamzadeh, F. N., & Surguchov, A.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-08-30
- Volume
- 12
- Pages
- 612-612
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2889197740
- Cited by
- 568
- References
- 147
- FWCI
- 24.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.